Immunotherapy of Pseudomonas Infections
Authors: KEHL MARKLEY
Journal: Annals of Internal Medicine (1967)

Editorial Notes1 February 1967Immunotherapy of Pseudomonas InfectionsKEHL MARKLEY, M.D.KEHL MARKLEY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-66-2-443 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAn increasingly serious problem for the past decade or more has been the rising prevalence of infections due to Pseudomonas aeruginosa. Pseudomonas bacteremia occurs in elderly, debilitated, and chronically ill patients, in premature infants, in patients treated with ionizing radiation, and in patients suffering from thermal burns. In leukemic and burned patients pseudomonas septicemia is the terminal cause of the majority of deaths.Therapy has been directed [1] toward treatment of the infection afterPseudomonashas been isolated from the blood stream or other tissues or [2] toward prophylaxis in those conditions that predispose to pseudomonas infections. Antibiotics such as...References1. VERDEREVANS EJ: A proposed antigenic schema for the identification of strains of Pseudomonas aeruginosa. J. Infect. Dis. 109: 183, 1961. CrossrefMedlineGoogle Scholar2. LIUABEBATES PVYJL: The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. J. Infect. Dis. 108: 218, 1961. CrossrefMedlineGoogle Scholar3. LIUMERCER PVCB: Growth, toxigenicity and virulence of Pseudomonas aeruginosa. J. Hyg. (Camb.) 61: 485, 1963. MedlineGoogle Scholar4. JACKSONHARTMAN EFW: Experimental bacillus pyocyaneus keratitis. J. Lab. Clin. Med. 12: 442, 1927. Google Scholar5. ROSENTHALMILLICANRUST SMRCJ: A factor in human gamma globulin preparations against Pseudomonas aeruginosa infections in mice. Proc. Soc. Exp. Biol. Med. 94: 214, 1957. CrossrefMedlineGoogle Scholar6. FISHERMANNING MWMC: Studies in the immunotherapy of bacterial infections. I. The comparative effectiveness of human gamma globulin against various bacterial species in mice. J. Immun. 81: 29, 1958. MedlineGoogle Scholar7. MILLICANRUST RCJD: Efficacy of rabbit pseudomonas antiserum in experimental Pseudomonas aeruginosa infection. J. Infect. Dis. 107: 389, 1960. CrossrefMedlineGoogle Scholar8. JONESJACKSONLOWBURY RJDMEJ: Antiserum and antibiotic in the prophylaxis of burns against Pseudomonas aeruginosa. Brit. J. Plast. Surg. 19: 43, 1966. CrossrefMedlineGoogle Scholar9. CHÜN-HSIANGCHIEN-YINHSING-MINCHÜN LHCS: Studies on septicemia in extensive burns. Chin. Med. J. (Peking) 83: 779, 1964. MedlineGoogle Scholar10. MILLICANEVANSMARKLEY RCGK: Susceptibility of burned mice to Pseudomonas aeruginosa and protection by vaccination. Ann. Surg. 163: 603, 1966. CrossrefMedlineGoogle Scholar11. KEFALIDESARANABAZANBOCANEGRASTASTNYVELARDEROSENTHAL NAJAAMPNSM: Role of infection in mortality from severe burns. Evaluation of plasma, gamma-globulin, albumin and saline solution therapy in a group of Peruvian children. New Eng. J. Med. 267: 317, 1962. CrossrefMedlineGoogle Scholar12. BODEYNIESMOHBERGFREIREICH GPBANREJ: Use of gamma globulin in infection in acute-leukemic patients. JAMA 190: 1099, 1964. CrossrefMedlineGoogle Scholar13. ROSENTHALHARTNEYSPURRIER SRJBWA: The "toxin-antitoxin" phenomenon in burned and injured subjects. JAMA 174: 957, 1960. CrossrefMedlineGoogle Scholar14. BOCANEGRAHINOSTROZABAZANVELARDEYOZAROSENTHAL MFANVSM: Convalescent burn plasma therapy for severely burned children. Ann. Surg. 163: 461, 1966. CrossrefMedlineGoogle Scholar15. FELLERKAMEI II: Pseudomonas vaccine and hyperimmune plasma in the treatment of burned patients. Surg. Forum 15: 46, 1964. MedlineGoogle Scholar16. ALEXANDERBROWNWALKERMASONMONCRIEF JWWHADJA: Studies on the isolation of an infection-protective agent from Pseudomonas aeruginosa. Surg. Gynec. Obstet. 123: 965, 1966. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: KEHL MARKLEY, M.D.Affiliations: Laboratory of Biochemical Pharmacology National Institute of Arthritis and Metabolic Diseases National Institutes of Health Bethesda, Md. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byO-Serotypes of Pseudomonas aeruginosa from animal and inanimate sources in Saudi ArabiaEvaluation of a new polyvalent Pseudomonas vaccine in respiratory infectionsNormally Occurring Precipitating Antibodies against Pseudomonas aeruginosaSpecificity of the protective response induced by the slime layer of Pseudomonas aeruginosaPseudomonas aeruginosa Vaccine in Cancer PatientsLOWELL S. YOUNG, M.D., RICHARD D. MEYER, M.D., DONALD ARMSTRONG, M.D., F.A.C.P.A Reduction of Pseudomonas Septicemias in Burned Patients By the Immune ProcessPseudomonas Abscess and Empyema of the Lung 1 February 1967Volume 66, Issue 2Page: 443-445KeywordsBacteremiaElderlyInfantsIonizing radiationProphylaxisPseudomonasPseudomonas aeruginosaPseudomonas infectionsRiversSepsis ePublished: 1 December 2008 Issue Published: 1 February 1967 PDF downloadLoading ...